# Pharmacokinetics of Nalbuphine After Intravenous and Intranasal Administration in Infants

> **NCT03059511** · PHASE1 · TERMINATED · sponsor: **University Children's Hospital, Zurich** · enrollment: 51 (actual)

## Conditions studied

- Pharmacokinetic

## Interventions

- **DRUG:** Nalbuphine

## Key facts

- **NCT ID:** NCT03059511
- **Lead sponsor:** University Children's Hospital, Zurich
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-03
- **Primary completion:** 2018-01-10
- **Final completion:** 2018-01-10
- **Target enrollment:** 51 (ACTUAL)
- **Why stopped:** We conclude that the doses we administered were safe, but too low. We plan to continue the study with higher doses (0.1 mg/kg iv and 0.2 mg/kg intranasal).
- **Last updated:** 2021-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03059511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03059511, "Pharmacokinetics of Nalbuphine After Intravenous and Intranasal Administration in Infants". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03059511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*